Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
2008/01/30 by Eugen Koren, Holly W. Smith, Elizabeth Shores +20 · 27 citations
Immunology and Microbiology · Medicine · Biochemistry, Genetics and Molecular Biology · #Biosimilars and Bioanalytical Methods #Monoclonal and Polyclonal Antibodies Research #Protein purification and stability
paper · doi:10.1016/j.jim.2008.01.001
Citations
Cited by
- Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodies
- Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics
- Antidrug antibody assay validation: industry survey results. [europepmc]
- T cell epitope: friend or foe? Immunogenicity of biologics in context. [europepmc]
- Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. [europepmc]
- Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. [europepmc]
- Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. [europepmc]
- Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity. [europepmc]
- A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. [europepmc]
- Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. [europepmc]
- Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. [europepmc]
- Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. [europepmc]
- Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes. [europepmc]
- Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and Semiquantitation. [europepmc]
- Assessing the Immunogenicity of Biopharmaceuticals. [europepmc]
- Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti-Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance. [europepmc]
- Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. [europepmc]
- Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers. [europepmc]
- In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development. [europepmc]
- Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives. [europepmc]
- Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. [europepmc]
- Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). [europepmc]
- Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies. [europepmc]
- T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020. [europepmc]
- Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays. [europepmc]
- Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies. [europepmc]
- T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics. [europepmc]